150 related articles for article (PubMed ID: 21709691)
21. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.
Powell IJ; Vigneau FD; Bock CH; Ruterbusch J; Heilbrun LK
Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1505-11. PubMed ID: 24802741
[TBL] [Abstract][Full Text] [Related]
22. Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy.
Trantham LC; Nielsen ME; Mobley LR; Wheeler SB; Carpenter WR; Biddle AK
Cancer; 2013 Oct; 119(19):3523-30. PubMed ID: 23893821
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.
Stephenson RA
Urol Clin North Am; 2002 Feb; 29(1):173-81. PubMed ID: 12109343
[TBL] [Abstract][Full Text] [Related]
25. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
26. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
27. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
28. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales.
Smith DP; Armstrong BK
Med J Aust; 1998 Jul; 169(1):17-20. PubMed ID: 9695696
[TBL] [Abstract][Full Text] [Related]
30. Reduced risk of prostate cancer in U.S. Men with AIDS.
Shiels MS; Goedert JJ; Moore RD; Platz EA; Engels EA
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2910-5. PubMed ID: 20837717
[TBL] [Abstract][Full Text] [Related]
31. The cost implications of prostate cancer screening in the Medicare population.
Ma X; Wang R; Long JB; Ross JS; Soulos PR; Yu JB; Makarov DV; Gold HT; Gross CP
Cancer; 2014 Jan; 120(1):96-102. PubMed ID: 24122801
[TBL] [Abstract][Full Text] [Related]
32. PSA measurement and prostate cancer--overdiagnosis and overtreatment?
Breidablik HJ; Meland E; Aakre KM; Førde OH
Tidsskr Nor Laegeforen; 2013 Sep; 133(16):1711-6. PubMed ID: 24005707
[TBL] [Abstract][Full Text] [Related]
33. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of localized prostate cancer following conservative management.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Barry MJ; Zietman A; O'Leary M; Walker-Corkery E; Yao SL
JAMA; 2009 Sep; 302(11):1202-9. PubMed ID: 19755699
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment.
Yeboa DN; Guzzo T; Mitra N; Christodouleas JP; Haas NB; Vapiwala N; Armstrong K; Bekelman JE
Urology; 2011 Nov; 78(5):1107-13. PubMed ID: 21943872
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
37. PSA screening among elderly men with limited life expectancies.
Walter LC; Bertenthal D; Lindquist K; Konety BR
JAMA; 2006 Nov; 296(19):2336-42. PubMed ID: 17105796
[TBL] [Abstract][Full Text] [Related]
38. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
39. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.
Aizer AA; Gu X; Chen MH; Choueiri TK; Martin NE; Efstathiou JA; Hyatt AS; Graham PL; Trinh QD; Hu JC; Nguyen PL
J Natl Compr Canc Netw; 2015 Jan; 13(1):61-8. PubMed ID: 25583770
[TBL] [Abstract][Full Text] [Related]
40. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
